HR | 95%CI | p | |
---|---|---|---|
Age (years) | |||
Range (26–74) | |||
Median: 49.5 | |||
< 50 | |||
≥ 50 | 1.2 | 0.7–2.3 | 0.5 |
VD level | |||
< 20 ng/mL | |||
≥ 20 ng/mL | 1.03 | 0.6–1.8 | 0.9 |
Clinical stage | |||
I-II | |||
III | 2.8 | 1.6–5.0 | 0.001 |
Tumor subtypes | |||
HER2+ | 1.77 | 0.8–4.1 | 0.1 |
HR+/HER2- | |||
TNBC | 6.5 | 3.1–13.7 | 0.0001 |
pCR | |||
no | |||
yes | 0.2 | 0.09–0.5 | 0.001 |
SBR grade | |||
II | |||
III | 0.86 | 0.5–1.6 | 0.6 |